Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
25 avr. 2024 07h00 HE
|
Purple Biotech Ltd.
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) --...
Pancreatic Cancer Drugs Global Market Report 2024
07 mars 2024 04h09 HE
|
Research and Markets
Dublin, March 07, 2024 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The pancreatic cancer drugs market size...
Triple Negative Breast Cancer Market Analysis and Insights Reveal Dynamic Shifts and Future Growth Projections to 2032
24 janv. 2024 10h36 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's...
Cholangiocarcinoma Market revenue to hit USD 1.3 Billion by 2036, says Research Nester
07 déc. 2023 06h30 HE
|
Research Nester
New York , Dec. 07, 2023 (GLOBE NEWSWIRE) -- The global cholangiocarcinoma market size is projected to grow at a CAGR of over 4% from 2024 to 2036. The market is expected to garner a revenue of USD...
Global Pancreatic Cancer Opportunity Analysis and Forecasts Report 2020: Market Expected to Grow at 11.5% CAGR to $5.4B During 2019-2029
06 janv. 2021 11h03 HE
|
Research and Markets
Dublin, Jan. 06, 2021 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering. Pancreatic cancer is...
PharmaCyte Biotech Addressing Unmet Need in Patients with LAPC as Pancreatic Cancer 5-Year Survival Rate Increases to 10%
14 janv. 2020 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 14, 2020 (GLOBE NEWSWIRE) -- This month the American Cancer Society announced that for the first time ever, the 5-year survival rate for pancreatic cancer has reached double...
World-Renowned Oncologist Bullish on Potential of PharmaCyte’s Technology, Clinical Trial in Pancreatic Cancer
23 janv. 2019 09h25 HE
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 23, 2019 (GLOBE NEWSWIRE) -- With PharmaCyte Biotech, Inc.’s (OTCQB: PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct...
PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer
21 mai 2018 09h20 HE
|
PharmaCyte Biotech
NEW YORK, NY, May 21, 2018 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reached the proverbial “home stretch” regarding its efforts to submit an Investigational New Drug Application...
PharmaCyte Biotech Moves Closer to Revealing Plan to Address Unmet Medical Need in Phase 2b Clinical Trial
30 sept. 2015 09h30 HE
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - September 30, 2015) - Cancer is the world's second most common cause of death, not too far behind heart disease. And, although no form of cancer is "good," pancreatic cancer...
PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status
18 mars 2015 09h00 HE
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - March 18, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns...